Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs MK 8353 (Primary) ; Selumetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 28 Feb 2019 Status changed from not yet recruiting to recruiting.
- 29 Jan 2019 Planned End Date changed from 6 May 2022 to 27 Jun 2022.
- 29 Jan 2019 Planned primary completion date changed from 6 May 2022 to 27 Jun 2022.